A necroptosis-relevant risk model was developed for predicting pancreatic cancer survival and responses to immuno- and chemotherapy, comprising MYEOV, HDAC4, TLDC1, PITPNA, FNDC3B, HMGXB4, and BAX. Here, MYEOV is linked to familial pancreatic carcinoma.